170 related articles for article (PubMed ID: 35844991)
1. Decitabine mildly attenuates
Schneider P; Castro PG; Pinhanços SM; Kerstjens M; van Roon EH; Essing AHW; Dolman MEM; Molenaar JJ; Pieters R; Stam RW
EJHaem; 2020 Nov; 1(2):527-536. PubMed ID: 35844991
[No Abstract] [Full Text] [Related]
2. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric
Kerstjens M; Garrido Castro P; Pinhanços SS; Schneider P; Wander P; Pieters R; Stam RW
Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34201500
[TBL] [Abstract][Full Text] [Related]
4. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
5. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.
Roolf C; Richter A; Konkolefski C; Knuebel G; Sekora A; Krohn S; Stenzel J; Krause BJ; Vollmar B; Murua Escobar H; Junghanss C
J Hematol Oncol; 2018 May; 11(1):62. PubMed ID: 29728108
[TBL] [Abstract][Full Text] [Related]
6. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
Front Oncol; 2022; 12():863329. PubMed ID: 35677155
[TBL] [Abstract][Full Text] [Related]
7. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
9. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
10. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract][Full Text] [Related]
14. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
15. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
16. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells.
Accordi B; Galla L; Milani G; Curtarello M; Serafin V; Lissandron V; Viola G; te Kronnie G; De Maria R; Petricoin EF; Liotta LA; Indraccolo S; Basso G
Leukemia; 2013 Apr; 27(5):1019-27. PubMed ID: 23228943
[TBL] [Abstract][Full Text] [Related]
17. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
18. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of Carfilzomib for Infant
Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
Front Oncol; 2021; 11():631594. PubMed ID: 33937032
[TBL] [Abstract][Full Text] [Related]
20. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
